KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Common Equity (2016 - 2025)

Historic Common Equity for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $48.8 million.

  • Halozyme Therapeutics' Common Equity fell 8658.3% to $48.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $48.8 million, marking a year-over-year decrease of 8658.3%. This contributed to the annual value of $48.8 million for FY2025, which is 8658.3% down from last year.
  • Per Halozyme Therapeutics' latest filing, its Common Equity stood at $48.8 million for Q4 2025, which was down 8658.3% from $503.9 million recorded in Q3 2025.
  • Halozyme Therapeutics' Common Equity's 5-year high stood at $503.9 million during Q3 2025, with a 5-year trough of $48.8 million in Q4 2025.
  • Its 5-year average for Common Equity is $234.4 million, with a median of $223.1 million in 2021.
  • Per our database at Business Quant, Halozyme Therapeutics' Common Equity soared by 33411.25% in 2024 and then plummeted by 8658.3% in 2025.
  • Over the past 5 years, Halozyme Therapeutics' Common Equity (Quarter) stood at $197.0 million in 2021, then dropped by 13.79% to $169.8 million in 2022, then crashed by 50.64% to $83.8 million in 2023, then soared by 334.11% to $363.8 million in 2024, then tumbled by 86.58% to $48.8 million in 2025.
  • Its Common Equity stands at $48.8 million for Q4 2025, versus $503.9 million for Q3 2025 and $332.7 million for Q2 2025.